Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN010
MIFTS: 57

Urinary Tract Obstruction

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary Tract Obstruction

About this section

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 73
Obstructive Uropathy 12 55
Urinary Obstruction 12
Urologic Diseases 73

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:5200
ICD10 33 N13.9
ICD9CM 35 599.6 599.60
NCIt 50 C3675 C79805
SNOMED-CT 68 7163005
Sources

Summaries for Urinary Tract Obstruction

About this section
MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to obstructive nephropathy and interstitial cystitis, and has symptoms including dysuria, polyuria and renal colic. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Tamsulosin and Adrenergic alpha-1 Receptor Antagonists have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and spinal cord, and related phenotypes are growth/size/body region and behavior/neurological

Sources

Related Diseases for Urinary Tract Obstruction

About this section

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 obstructive nephropathy 31.4 ALB EGF REN SMAD2 SMAD3 TGFB1
2 interstitial cystitis 30.3 EGF HBEGF UMOD
3 cystitis 30.3 CCL2 EGF HBEGF PTGS2 UMOD
4 cystic kidney disease 30.1 ALB B2M EGF UMOD
5 end stage renal failure 30.0 ALB TGFB1 UMOD
6 acute cystitis 30.0 ALB C16orf58 CCL2 KLK3
7 pyelonephritis 29.9 ALB CCL2 NAGLU UMOD
8 ureteral obstruction 29.9 AQP2 PTGS2 TGFB1
9 clear cell adenocarcinoma 29.8 KLK3 SMAD2 SMAD3
10 adenocarcinoma 29.7 EGF PIK3CA PTGS2 SMAD3
11 hydronephrosis 29.7 ALB AQP2 B2M CCL2 EGF NAGLU
12 vesicoureteral reflux 1 29.6 C16orf58 NAGLU REN UMOD
13 inflammatory bowel disease 29.5 ALB CCL2 PTGS2 SMAD2 SMAD3 TGFB1
14 renal fibrosis 29.3 CCL2 CCN2 REN SMAD2 SMAD3 TGFB1
15 kidney disease 28.9 ALB AQP2 B2M CCL2 CCN2 NAGLU
16 kashani strom utley syndrome 11.7
17 renal hypodysplasia/aplasia 1 11.4
18 cystinuria 11.4
19 renal hypodysplasia/aplasia 2 11.4
20 renal hypodysplasia/aplasia 3 11.2
21 congenital anomalies of kidney and urinary tract 2 11.1
22 small cell carcinoma of the bladder 11.0
23 inguinal hernia 10.3
24 submandibular gland disease 10.3 KLK3 TGFB1
25 adult hepatocellular carcinoma 10.3 EGF PIK3CA
26 ascending cholangitis 10.3 ALB CCL2 TGFB1
27 lipoid nephrosis 10.2 ALB CCL2 NAGLU
28 diabetic foot ulcers 10.2 CCL2 TGFB1
29 prostate transitional cell carcinoma 10.2 KLK3 PIK3CA
30 immunodeficiency 43 10.2 ALB B2M
31 tuberculous meningitis 10.2 CCL2 GGT1 TGFB1
32 prostate adenoid cystic carcinoma 10.2 KLK3 PIK3CA
33 prostate cancer 10.2
34 aortic aneurysm 10.2
35 leukoregulin 10.2 PTGS2 TGFB1
36 peyronie's disease 10.2 CCL2 SMAD3 TGFB1
37 benign essential hypertension 10.2 ALB REN
38 proteasome-associated autoinflammatory syndrome 1 10.2 ALB CCL2 PTGS2
39 aortic aneurysm, familial abdominal, 1 10.2
40 systemic lupus erythematosus 10.2
41 crohn's disease 10.2
42 lupus erythematosus 10.2
43 retroperitoneal fibrosis 10.2
44 respiratory system disease 10.2 ALB CCL2 TGFB1
45 peritonitis 10.2 ALB B2M CCL2
46 membranous nephropathy 10.2 ALB B2M TGFB1
47 kidney papillary necrosis 10.2 ALB REN
48 interstitial nephritis 10.1 ALB REN UMOD
49 intestinal disease 10.1 ALB PIK3CA PTGS2
50 chagas disease 10.1 CCL2 SMAD2 TGFB1

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction
Sources

Symptoms & Phenotypes for Urinary Tract Obstruction

About this section

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, renal colic, urgency of micturition, other and unspecified genitourinary symptoms, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 AQP2 B2M CCN2 EGF GGT1 HBEGF
2 behavior/neurological MP:0005386 10.35 AQP2 GGT1 HBEGF NAGLU PIK3CA PTGS2
3 homeostasis/metabolism MP:0005376 10.35 ALB AQP2 B2M CCN2 GGT1 HBEGF
4 cardiovascular system MP:0005385 10.3 B2M CCN2 HBEGF NAGLU PIK3CA PTGS2
5 immune system MP:0005387 10.3 B2M CCL2 EGF GGT1 NAGLU PIK3CA
6 cellular MP:0005384 10.29 ALB B2M CCN2 GGT1 NAGLU PIK3CA
7 endocrine/exocrine gland MP:0005379 10.26 ALB B2M CCN2 EGF GGT1 PIK3CA
8 mortality/aging MP:0010768 10.24 ALB AQP2 B2M CCN2 GGT1 HBEGF
9 integument MP:0010771 10.21 AQP2 B2M CCN2 EGF GGT1 HBEGF
10 digestive/alimentary MP:0005381 10.19 ALB B2M CCN2 EGF PTGS2 SLC5A6
11 hematopoietic system MP:0005397 10.19 AQP2 B2M GGT1 NAGLU PTGS2 REN
12 liver/biliary system MP:0005370 10.06 ALB B2M CCN2 NAGLU PTGS2 SLC5A6
13 renal/urinary system MP:0005367 9.96 ALB AQP2 GGT1 NAGLU PTGS2 REN
14 neoplasm MP:0002006 9.87 ALB B2M PIK3CA PTGS2 SMAD2 SMAD3
15 reproductive system MP:0005389 9.85 AQP2 B2M EGF GGT1 PIK3CA PTGS2
16 skeleton MP:0005390 9.7 CCN2 GGT1 HBEGF NAGLU PIK3CA PTGS2
17 vision/eye MP:0005391 9.28 CCN2 EGF GGT1 NAGLU PIK3CA PTGS2
Sources

Drugs & Therapeutics for Urinary Tract Obstruction

About this section

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106133-20-4 129211
2 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
3 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Tolterodine tartrate Phase 4 124937-52-6
5 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
6 Muscarinic Antagonists Phase 4
7 Cholinergic Antagonists Phase 4
8 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
9 Cholinergic Agents Phase 4
10 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
12
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
13
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
14
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
15
Leuprolide Approved, Investigational Phase 3,Phase 2 53714-56-0 657181 3911
16
Flutamide Approved, Investigational Phase 3 13311-84-7 3397
17
Nilutamide Approved, Investigational Phase 3 63612-50-0 4493
18
Bicalutamide Approved Phase 3 90357-06-5 2375 56069
19
Salicylic acid Approved, Investigational, Vet_approved Phase 3 69-72-7 338
20
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
21
Artemether Approved Phase 3 71963-77-4 119380 68911
22
Acetaminophen Approved Phase 3 103-90-2 1983
23
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
24
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
25
Lumefantrine Approved Phase 3 82186-77-4 6437380
26
Cortisone Experimental Phase 3 53-06-5 222786
27 carnitine Phase 3
28 Anti-Bacterial Agents Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Anti-Infective Agents Phase 3,Phase 1
31 Omega 3 Fatty Acid Phase 3
32 Analgesics, Non-Narcotic Phase 3
33 Arginine Vasopressin Phase 3
34 arginine Phase 3
35 Deamino Arginine Vasopressin Phase 3
36 Coagulants Phase 3
37 Anti-Inflammatory Agents Phase 3,Phase 2
38 Hemostatics Phase 3
39 Analgesics Phase 3
40 Peripheral Nervous System Agents Phase 3
41 Antirheumatic Agents Phase 3
42 Natriuretic Agents Phase 3
43 Vasopressins Phase 3
44 Cyclooxygenase Inhibitors Phase 3
45 Tocolytic Agents Phase 3
46 Anti-Inflammatory Agents, Non-Steroidal Phase 3
47 Hormones Phase 3,Phase 2
48 Antineoplastic Agents, Hormonal Phase 3,Phase 2
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
50 Hormone Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
2 Functional MR Urography Completed NCT00301470 Phase 4
3 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
4 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
5 Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
6 Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence Unknown status NCT02112591 Phase 3
7 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
8 Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting NCT03678025 Phase 3 Abiraterone;Bicalutamide;Degarelix;Docetaxel;Flutamide;Goserelin Acetate;Histrelin Acetate;Leuprolide Acetate;Nilutamide;Prednisone;Triptorelin
9 Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria Recruiting NCT03056391 Phase 3 Paracetamol
10 Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
11 Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
12 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed NCT01718353 Phase 2 DOCETAXEL (XRP6976);CABAZITAXEL (XRP6258);Prednisone
13 Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms Completed NCT02244281 Phase 2 tamsulosin hydrochloride;Placebo
14 Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Completed NCT01750398 Phase 2 Testosterone cypionate;Goserelin;Leuprolide
15 Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Completed NCT00527488 Phase 2 Degarelix;Degarelix;Degarelix;Degarelix
16 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
17 ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. Recruiting NCT02933801 Phase 2 ODM-201
18 Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Active, not recruiting NCT02286921 Phase 2 Testosterone cypionate;Enzalutamide;Testosterone Enanthate
19 Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery Not yet recruiting NCT03541850 Phase 2 Antiandrogen Therapy
20 Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Terminated NCT01919346 Phase 2 Eculizumab;Normal Saline
21 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma Completed NCT00315731 Phase 1
22 Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia Not yet recruiting NCT03723564 Phase 1 Lactated Ringers Solution for Injection
23 Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria Unknown status NCT02139059 Not Applicable
24 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907 Not Applicable
25 Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment Completed NCT03280420 Not Applicable
26 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
27 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage Completed NCT02055430 Not Applicable
28 Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) Completed NCT02398682 Not Applicable
29 Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men Completed NCT02330107 Not Applicable
30 Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO) Recruiting NCT03281798 Not Applicable
31 Standardized Prenatal Clinical Care for LUTO Recruiting NCT02315521
32 Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL) Recruiting NCT03605745 Not Applicable
33 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia Recruiting NCT03055624 Not Applicable
34 Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate Recruiting NCT03034187
35 Short Course Radiation Therapy in Palliative Treatment of Pelvic Cancer Recruiting NCT03804333 Not Applicable
36 Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate Recruiting NCT03157726 Not Applicable
37 Green LEP vs ThuLEP vs HoLEP in Management of Marked Enlarged Prostate Active, not recruiting NCT03305861 Not Applicable
38 Indwelling Stent Discoloration Project Active, not recruiting NCT02007980
39 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT Enrolling by invitation NCT03589196 Not Applicable
40 Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence Enrolling by invitation NCT02578056 Not Applicable
41 Fetal Cystoscopy for Lower Urinary Tract Obstruction Terminated NCT02446184 Not Applicable
42 Tc-99m Renography and Cisplatin-induced Nephrotoxicity Terminated NCT00213642
43 Functional, Dynamic, and Anatomic MR Urography Withdrawn NCT00585767

Search NIH Clinical Center for Urinary Tract Obstruction

Sources

Genetic Tests for Urinary Tract Obstruction

About this section
Sources

Anatomical Context for Urinary Tract Obstruction

About this section

MalaCards organs/tissues related to Urinary Tract Obstruction:

41
Kidney, Prostate, Spinal Cord, Neutrophil, Cervix, Lung, Testes
Sources

Publications for Urinary Tract Obstruction

About this section

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 959)
# Title Authors Year
1
Perinatal Outcomes of Fetal Lower Urinary Tract Obstruction After Vesicoamniotic Shunting Using a Double-Basket Catheter. ( 29498072 )
2018
2
Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )
2018
3
Current State of Fetal Intervention for Lower Urinary Tract Obstruction. ( 29468448 )
2018
4
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction. ( 29644715 )
2018
5
Successful medical management of pseudomembranous cystitis in three cats with lower urinary tract obstruction. ( 29226304 )
2018
6
SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. ( 29852947 )
2018
7
Long-term renal outcome in infants with congenital lower urinary tract obstruction. ( 29980359 )
2018
8
A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. ( 29664229 )
2018
9
Antenatal staging of congenital lower urinary tract obstruction. ( 29978555 )
2018
10
Hemoadsorption in a Case of Severe Septic Shock and Necrotizing Fasciitis Caused by Nontraumatic Renal Rupture due to Pyelonephritis with Obstructive Uropathy. ( 29854478 )
2018
11
An Interesting Case of a 57-Year-Old Male with an Upper Gastrointestinal Bleeding and Obstructive Uropathy with Bilateral Hydronephrosis Diagnosed with Systemic Mucormycosis. ( 30026991 )
2018
12
Obstructive Uropathy Secondary to an Indirect Extraperitoneal Ureteral Inguinal Hernia. ( 30401039 )
2018
13
Obstructive Uropathy Secondary to an Indirect Extraperitoneal Ureteral Inguinal Hernia. ( 30454446 )
2018
14
Inguinal hernia causing extrinsic compression of bilateral ureters leading to chronic obstructive uropathy. ( 29644043 )
2018
15
Obstructive uropathy from complete bladder and bilateral ureteral incarceration within an inguinal hernia. ( 29487099 )
2018
16
The uroplakin plaque promotes renal structural integrity during congenital and acquired urinary tract obstruction. ( 29897287 )
2018
17
Extracorporeal membrane oxygenation support in a newborn with lower urinary tract obstruction and pulmonary hypoplasia: a case report. ( 30012211 )
2018
18
Surgical interventions and anesthesia in the 1st year of life for lower urinary tract obstruction. ( 30049573 )
2018
19
Prenatal renal parenchymal area as a predictor of early end-stage renal disease in children with vesicoamniotic shunting for lower urinary tract obstruction. ( 30093259 )
2018
20
ARFI shear-wave elastography with simulation of acute urinary tract obstruction in an ex vivo porcine kidney model. ( 30211684 )
2018
21
Antenatal intervention for congenital fetal lower urinary tract obstruction (LUTO): a systematic review and meta-analysis. ( 30501534 )
2018
22
The search for the definition and effective diagnosis of upper urinary tract obstruction: the Whitaker test then and now, Whitaker et al. 2018. ( 30528651 )
2018
23
Cloacal Anomalies in Monoamniotic, Monochorionic Twins with Complete Urinary Tract Obstruction. ( 30540986 )
2018
24
Laparoscopic resection of large pelvic lipoma causing obstructive uropathy in a 66 year old female - A case report from Greece. ( 30317275 )
2018
25
An Unusual Presentation of Metastatic Urothelial Bladder Carcinoma With Rhabdoid Features Presenting as Obstructive Uropathy. ( 29288786 )
2018
26
Obstructive uropathy in a patient with double district ureter. ( 29229357 )
2018
27
Value of Magnetic Resonance Urography Versus Computerized Tomography Urography (CTU) in Evaluation of Obstructive Uropathy: An Observational Study. ( 29399012 )
2018
28
Urinary antimicrobial peptides: Potential novel biomarkers of obstructive uropathy. ( 29706289 )
2018
29
The results of ultrasound-guided percutaneous nephrostomy tube placement for obstructive uropathy: A single-centre 10-year experience. ( 29799408 )
2018
30
Unusual cause of obstructive uropathy: bilateral steinstrasse. ( 29871965 )
2018
31
From a stone to rupture: calyceal rupture secondary to obstructive uropathy. ( 29881597 )
2018
32
Obstructive Uropathy and Sepsis Caused by an Inguinoscrotal Bladder Hernia: A Case Report. ( 30005731 )
2018
33
Assessment of the relation between pelvicalyceal dilatation in ultrasound and features of obstructive uropathy in dynamic renal scintigraphy. ( 30070349 )
2018
34
Antireflux ureteral stent proof of concept assessment after minimally invasive treatment of obstructive uropathy in animal model. ( 30198852 )
2018
35
Traditional Chinese medicine decreases the obstructive uropathy risk in uterovaginal prolapse: A nationwide population-based study. ( 30235697 )
2018
36
Common clinical markers predict end-stage renal disease in children with obstructive uropathy. ( 30317433 )
2018
37
Primary pelvic hydatid cyst: A rare case presenting with obstructive uropathy. ( 30447550 )
2018
38
Three-dimensional virtual cystoscopy: Noninvasive approach for the assessment of urinary tract in fetuses with lower urinary tract obstruction. ( 29178428 )
2017
39
Complete upper urinary tract obstruction caused by penetrating pellet injury of the ureterintroduction. ( 28513528 )
2017
40
Can bladder fibrosis in congenital urinary tract obstruction be reversed? ( 29037864 )
2017
41
Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. ( 28700992 )
2017
42
Forkhead box O3 (FoxO3) regulates kidney tubular autophagy following urinary tract obstruction. ( 28705935 )
2017
43
Influence of bladder fullness on the detection of urinary tract obstruction by dynamic renal scintigraphy. ( 28894331 )
2017
44
Ultrasound guided balloon catheterisation: a new method of fetal lower urinary tract obstruction management. ( 28580571 )
2017
45
Early vesico-amniotic shunting - does it change the prognosis in fetal lower urinary tract obstruction diagnosed in the first trimester? ( 29057434 )
2017
46
Fetal surgery for lower urinary tract obstruction: the importance of staging prior to intervention. ( 29160637 )
2017
47
Lower urinary tract obstruction: fetal intervention based on prenatal staging. ( 28730376 )
2017
48
Spontaneous rupture of the renal pelvis caused by upper urinary tract obstruction: A case report and review of the literature. ( 29390332 )
2017
49
Diagnostic value of 64-slice spiral computed tomography imaging of the urinary tract during the excretory phase for urinary tract obstruction. ( 29201177 )
2017
50
Detection of obstructive uropathy and assessment of differential renal function using two functional magnetic resonance urography tools. A comparison with diuretic renal scintigraphy in infants and children. ( 27683747 )
2017
Sources

Variations for Urinary Tract Obstruction

About this section
Sources

Expression for Urinary Tract Obstruction

About this section
Search GEO for disease gene expression data for Urinary Tract Obstruction.
Sources

Pathways for Urinary Tract Obstruction

About this section

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.31 B2M CCL2 EGF HBEGF PIK3CA PTGS2
2
Human cytomegalovirus infection 37
Show member pathways
 12.99 B2M CCL2 PIK3CA PTGS2 SMAD3 TGFB1
3
p70S6K Signaling 64
Show member pathways
 12.98 CCL2 CCN2 EGF HBEGF PTGS2 REN
4
Endometrial cancer 37
Show member pathways
 12.8 EGF KLK3 PIK3CA SMAD2 SMAD3 TGFB1
5
Gastric cancer 37
Show member pathways
 12.71 EGF PIK3CA SMAD2 SMAD3 TGFB1
6
Pathways in cancer 37
12.67 EGF KLK3 PIK3CA PTGS2 SMAD2 SMAD3
7
ErbB signaling pathway 1 37
Show member pathways
 12.42 EGF HBEGF PIK3CA TGFB1
8
Development EGFR signaling pathway 22
Show member pathways
 12.42 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1
9
Human T-cell leukemia virus 1 infection 37
12.37 PIK3CA SMAD2 SMAD3 TGFB1
10
Selenium Micronutrient Network 1
Show member pathways
 12.27 ALB CCL2 GGT1 PTGS2
11
Proteoglycans in cancer 37
12.22 HBEGF PIK3CA SMAD2 TGFB1
12
Wnt / Hedgehog / Notch 4
12.17 CCN2 SMAD2 SMAD3 TGFB1
13
Cellular senescence (KEGG) 37
12.1 PIK3CA SMAD2 SMAD3 TGFB1
14
Colorectal Cancer Metastasis 64
12.09 EGF PTGS2 SMAD2 SMAD3 TGFB1
15
Hippo signaling pathway 37
12.08 CCN2 SMAD2 SMAD3 TGFB1
16
NRF2 pathway 1
12.05 GGT1 HBEGF SLC5A6 TGFB1
17
FoxO signaling pathway 37
Show member pathways
 11.86 EGF PIK3CA SMAD2 SMAD3 TGFB1
18
TGF-beta Signaling Pathways 65
11.83 SMAD2 SMAD3 TGFB1
19
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.81 SMAD2 SMAD3 TGFB1
20
Angiogenesis (CST) 4
11.77 CCL2 PTGS2 REN TGFB1
21
TGF-beta signaling pathway (KEGG) 37
11.76 SMAD2 SMAD3 TGFB1
22
Loss of Function of SMAD2/3 in Cancer 66
Show member pathways
 11.72 SMAD2 SMAD3 TGFB1
23
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.71 CCL2 CCN2 EGF PIK3CA SMAD2 SMAD3
24
Development_TGF-beta receptor signaling 22
11.68 SMAD2 SMAD3 TGFB1
25
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.67 CCL2 PTGS2 TGFB1
26
TGF-beta receptor signaling activates SMADs 66
Show member pathways
 11.66 SMAD2 SMAD3 TGFB1
27
AGE-RAGE signaling pathway in diabetic complications 37
11.65 CCL2 PIK3CA SMAD2 SMAD3 TGFB1
28
Regulation of Telomerase 1
11.62 EGF SMAD3 TGFB1
29
Lung fibrosis 1
11.6 CCL2 CCN2 EGF TGFB1
30
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.6 EGF HBEGF KLK3 PIK3CA SMAD3 TGFB1
31
TGF-beta Receptor Signaling (WikiPathways) 1
11.5 EGF SMAD2 SMAD3 TGFB1
32
Hepatitis C and Hepatocellular Carcinoma 1
11.49 PTGS2 SMAD3 TGFB1
33
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.38 CCN2 SMAD2 SMAD3 TGFB1
34
Extracellular vesicle-mediated signaling in recipient cells 1
11.22 SMAD2 SMAD3 TGFB1
35
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.12 CCN2 SMAD2 SMAD3
36
IL1 and megakaryocytes in obesity 1
11.11 CCL2 HBEGF PIK3CA
37
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.94 SMAD2 SMAD3 TGFB1
38
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 10.79 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1
Sources

GO Terms for Urinary Tract Obstruction

About this section

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 ALB AQP2 B2M EGF GGT1 KLK3
2 extracellular region GO:0005576 9.7 ALB B2M CCL2 CCN2 EGF HBEGF
3 platelet alpha granule lumen GO:0031093 9.54 ALB EGF TGFB1
4 extracellular space GO:0005615 9.36 ALB B2M CCL2 CCN2 EGF GGT1
5 SMAD protein complex GO:0071141 9.32 SMAD2 SMAD3
6 heteromeric SMAD protein complex GO:0071144 9.16 SMAD2 SMAD3

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.98 CCL2 PIK3CA PTGS2 TGFB1
2 positive regulation of cell migration GO:0030335 9.96 EGF HBEGF SMAD3 TGFB1
3 MAPK cascade GO:0000165 9.93 CCL2 EGF HBEGF TGFB1
4 cell migration GO:0016477 9.91 CCN2 HBEGF PIK3CA TGFB1
5 positive regulation of protein kinase B signaling GO:0051897 9.88 EGF HBEGF PIK3CA TGFB1
6 response to lipopolysaccharide GO:0032496 9.87 GGT1 PTGS2 REN SLPI
7 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 SMAD2 SMAD3 TGFB1
8 wound healing GO:0042060 9.85 SMAD2 SMAD3 TGFB1
9 response to organic substance GO:0010033 9.85 PTGS2 REN TGFB1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 EGF HBEGF TGFB1
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 PIK3CA PTGS2 TGFB1
12 response to glucose GO:0009749 9.81 CCN2 SMAD2 TGFB1
13 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.81 SMAD2 SMAD3 TGFB1
14 SMAD protein signal transduction GO:0060395 9.77 SMAD2 SMAD3 TGFB1
15 response to estradiol GO:0032355 9.73 CCN2 GGT1 PTGS2 TGFB1
16 positive regulation of epithelial to mesenchymal transition GO:0010718 9.72 SMAD2 SMAD3 TGFB1
17 angiogenesis GO:0001525 9.72 CCL2 CCN2 EGF PIK3CA PTGS2
18 ureteric bud development GO:0001657 9.71 SMAD2 SMAD3 TGFB1
19 protein kinase B signaling GO:0043491 9.69 CCL2 PIK3CA TGFB1
20 zymogen activation GO:0031638 9.68 GGT1 KLK3
21 lens fiber cell differentiation GO:0070306 9.67 SMAD3 TGFB1
22 positive regulation of protein import into nucleus GO:0042307 9.67 PTGS2 SMAD3 TGFB1
23 nodal signaling pathway GO:0038092 9.65 SMAD2 SMAD3
24 primary miRNA processing GO:0031053 9.65 SMAD2 SMAD3
25 endoderm development GO:0007492 9.65 SMAD2 SMAD3 TGFB1
26 response to cholesterol GO:0070723 9.64 SMAD2 TGFB1
27 ERBB2 signaling pathway GO:0038128 9.63 EGF HBEGF PIK3CA
28 embryonic foregut morphogenesis GO:0048617 9.62 SMAD2 SMAD3
29 pericardium development GO:0060039 9.62 SMAD2 SMAD3
30 common-partner SMAD protein phosphorylation GO:0007182 9.58 SMAD2 TGFB1
31 positive regulation of extracellular matrix assembly GO:1901203 9.56 SMAD3 TGFB1
32 regulation of striated muscle tissue development GO:0016202 9.52 SMAD3 TGFB1
33 epidermal growth factor receptor signaling pathway GO:0007173 9.46 EGF HBEGF PIK3CA TGFB1
34 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.43 SMAD2 SMAD3 TGFB1
35 evasion or tolerance of host defenses by virus GO:0019049 9.4 SMAD3 TGFB1
36 paraxial mesoderm morphogenesis GO:0048340 9.37 SMAD2 SMAD3
37 SMAD protein complex assembly GO:0007183 9.13 SMAD2 SMAD3 TGFB1
38 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 TGFB1
39 positive regulation of cell proliferation GO:0008284 10.07 CCN2 EGF HBEGF PTGS2 TGFB1
40 negative regulation of cell proliferation GO:0008285 10.01 PTGS2 SMAD2 SMAD3 TGFB1 UMOD
41 positive regulation of gene expression GO:0010628 10 CCN2 EGF SMAD2 SMAD3 TGFB1

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGF HBEGF PIK3CA
2 growth factor activity GO:0008083 9.46 CCN2 EGF HBEGF TGFB1
3 enhancer binding GO:0035326 9.43 SMAD2 SMAD3
4 co-SMAD binding GO:0070410 9.4 SMAD2 SMAD3
5 type I transforming growth factor beta receptor binding GO:0034713 9.37 SMAD2 TGFB1
6 primary miRNA binding GO:0070878 9.26 SMAD2 SMAD3
7 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD2 SMAD3
8 transforming growth factor beta receptor binding GO:0005160 8.8 SMAD2 SMAD3 TGFB1
Sources

Sources for Urinary Tract Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....